Source-grounded facts extracted from Rani Therapeutics Holdings, Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Rani Therapeutics Holdings, Inc. shareholders approved Ratification of CBIZ CPAs P.C. as the independent registered public accounting firm for fiscal year ending December 31, 2026 at the 2026-05-28 meeting.
“The Company’s stockholders ratified the appointment of CBIZ CPAs P.C. as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026, as follows: For: 77,019,828 Against: 332,645 Abstain: 54,190”
Rani Therapeutics Holdings, Inc. shareholders approved Election of director nominees to hold office until the 2027 annual meeting at the 2026-05-28 meeting.
“The following is a summary of the matters voted on at the Annual Meeting based on the report of the voting results by the inspector of election.”
Rani Therapeutics Holdings, Inc. reported the first quarter ended March 31, 2026 results: revenue $1.7 million, net income $8.0 million.
“and license agreement with Chugai, to be sufficient to fund its operations into the fourth quarter of 2027. • Contract revenue for the three months ended March 31, 2026 were $1.7 million, compared to $0.2 million for the same period in 2025. The increase of $1.5 million was primarily attributable to the collaboration and license agreement with Chugai. • Research”
Rani Therapeutics Holdings, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5450(a)(1), 5810(c)(3)(A)).
“May 11, 2026, the Company received a letter from the Nasdaq Stock Exchange LLC (“Nasdaq”), notifying the Company that, based on the closing bid price of the Company’s Class A common stock, par value $0.0001 per share (th”
Svai Sanford departed as Chief Financial Officer at Rani Therapeutics Holdings, Inc..
“On May 12, 2026, Svai Sanford, the Company’s Chief Financial Officer, advised the Company that he will resign from his position following the appointment of his successor.”
Rani Therapeutics Holdings, Inc. reported fourth quarter and year ended December 31, 2025 results: revenue $1.5 million.
“to the Chugai agreement, to be sufficient to fund its operations into the fourth quarter of 2027. • Contract revenue for the three and twelve months ended December 31, 2025 were $1.5 million and $1.6 million, respectively. Of this, $1.5 million was attributed to a License and Collaboration Agreement and $0.1 million was attributed to evaluation services performed for”
Rani Therapeutics Holdings, Inc. issued common stock.
“As a result of the adoption of the Amended and Restated Certificate of Incorporation (as so amended and restated, the “Restated Charter”), the rights of holders of the Company’s common stock were materially modified, including, among other things, a reduction in the voting power of the Company’s Class B common stock from ten (10) votes per share to one (1) vote per share.”
Rani Therapeutics Holdings, Inc.: Adopted Amended and Restated Bylaws to reflect conforming changes resulting from the adoption of the Restated Charter (effective 2025-12-31).
“In connection with the adoption of the Restated Charter, on December 31, 2025, the Company also adopted Amended and Restated Bylaws (the “Bylaws”), which became effective on such date.”
Rani Therapeutics Holdings, Inc.: Filed Restated Charter which reduces Class B voting power from 10 to 1 vote per share, eliminates stockholder ability to act by written consent, opts into Section 203 DGCL, and includes other protective provisions (effective 2025-12-31).
“In connection with the governance changes contemplated by the Purchase Agreement, on December 31, 2025, the Company filed the Restated Charter with the Secretary of State of the State of Delaware, which became effective upon such filing.”
Rani Therapeutics Holdings, Inc. terminated TRA Termination Agreement with InCube Labs, LLC (effective 2025-12-31).
“the Company entered into a Tax Receivable Agreement Termination and Release Agreement (the “TRA Termination Agreement”) by and between the Company and InCube Labs, LLC (acting on behalf of all the TRA Parties (as defined therein)), pursuant to which the parties agreed to terminate that certain Tax Receivable Agreement, dated August 3, 2021 (the “TRA”)”
Rani Therapeutics Holdings, Inc. issued Warrants to purchase up to 12,500,000 shares of Class A Common Stock (or Pre-Funded Warrants in lieu thereof) of warrant to Avenue Venture Opportunities Fund, L.P. for part of conversion of $6.0 million of outstanding Loans.
“On October 16, 2025, the Company, Rani LLC and Avenue entered into an amendment to the Loan Agreement (the “LSA Amendment”), effective as of September 30, 2025, pursuant to which Avenue agreed to convert $6.0 million of outstanding Loans into 12,500,000 Shares (or Pre-Funded Warrants in lieu thereof) in connection with the Private Placement and will receive Warrants to purchase up to 12,500,000 shares of Class A Common Stock (or Pre-Funded Warrants in lieu thereof), on the same terms as the Purchasers.”
Rani Therapeutics Holdings, Inc. issued 12,500,000 Shares (or Pre-Funded Warrants in lieu thereof) of common stock to Avenue Venture Opportunities Fund, L.P. for conversion of $6.0 million of outstanding Loans.
“On October 16, 2025, the Company, Rani LLC and Avenue entered into an amendment to the Loan Agreement (the “LSA Amendment”), effective as of September 30, 2025, pursuant to which Avenue agreed to convert $6.0 million of outstanding Loans into 12,500,000 Shares (or Pre-Funded Warrants in lieu thereof) in connection with the Private Placement and will receive Warrants to purchase up to 12,500,000 shares of Class A Common Stock (or Pre-Funded Warrants in lieu thereof), on the same terms as the Purchasers.”
Rani Therapeutics Holdings, Inc. issued pre-funded warrants to purchase up to an aggregate of 82,366,667 shares of Class A Common Stock of warrant to institutional and accredited investors, and Mir Imran for $0.4799 per Pre-Funded Warrant.
“of 82,366,667 shares of Class A Common Stock (the “Pre-Funded Warrants”). Pursuant to the Purchase Agreement, the purchase price of the Shares to the Institutional Investors is $0.48 per share; and the Purchase Price of the Shares to the Affiliated Investor is $0.605 per share, which reflects the consolidated closing bid price of our Class A Common Stock on”
Rani Therapeutics Holdings, Inc. issued warrants to purchase up to an aggregate of 125,000,004 shares of Class A Common Stock of warrant to institutional and accredited investors, and Mir Imran for Part of purchase price per share and Common Warrant; exercise price $0.48 per share.
“of 82,366,667 shares of Class A Common Stock (the “Pre-Funded Warrants”). Pursuant to the Purchase Agreement, the purchase price of the Shares to the Institutional Investors is $0.48 per share; and the Purchase Price of the Shares to the Affiliated Investor is $0.605 per share, which reflects the consolidated closing bid price of our Class A Common Stock on”
Rani Therapeutics Holdings, Inc. issued 42,633,337 shares of Class A common stock of common stock to institutional and accredited investors, and Mir Imran for $0.48 per share to Institutional Investors; $0.605 per share to Affiliated Investor; aggregate gross proceeds approximately $60.3 million.
“of 82,366,667 shares of Class A Common Stock (the “Pre-Funded Warrants”). Pursuant to the Purchase Agreement, the purchase price of the Shares to the Institutional Investors is $0.48 per share; and the Purchase Price of the Shares to the Affiliated Investor is $0.605 per share, which reflects the consolidated closing bid price of our Class A Common Stock on”
Rani Therapeutics Holdings, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5450(a)(1), 5810(c)(3)(A)).
“June 20, 2025, Rani Therapeutics Holdings, Inc. (“Company”) received a letter (“Notice”) from the Nasdaq Stock Exchange LLC (“Nasdaq”), notifying Company that, based on the closing bid price of the Company’s Class A common stock, par value $0.0001 per share (the “Common Stock”), for the prior 30 consecutive business days the Company no longer complies with the minimum bid price requirement for continued listing on The Nasdaq Global Market. Nasdaq Listing Rule 5450(a)(1) requires listed securities to maintain a minimum bid price of $1.00 per share (the “Minimum Bid Price Requirement”). Under Na”
Rani Therapeutics Holdings, Inc. received a nasdaq deficiency notice notice regarding market value (rules 5450(b)(2)(A), 5810(c)(3)(C)).
“May 1, 2025, Rani Therapeutics Holdings, Inc. (“Company”) received a letter (“Notice”) from the Nasdaq Stock Exchange LLC (“Nasdaq”), addressing a compliance deficiency under the Nasdaq Listing Rules. The letter notified of the deficiency with regard to Rule 5450(b)(2)(A), which requires a company whose securities are listed on The Nasdaq Global Market under the “Market Value Standard” to maintain a minimum Market Value of Listed Securities (an “MVLS”) of $50,000,000. The deficiency was caused by the Company’s MVLS having been below the minimum level for the prior 30 consecutive business days.”
Laureen DeBuono retired as Director at Rani Therapeutics Holdings, Inc..
“On April 24, 2025, Laureen DeBuono notified the Board of Directors (“Board”) of Rani Therapeutics Holdings, Inc. (the “Company”) that she has decided to retire from the Board effective immediately.”
Rani Therapeutics Holdings, Inc. engaged CBIZ CPAs P.C. as its auditor.
“The Audit Committee approved the appointment of CBIZ CPAs P.C. ("CBIZ") as the Company's new independent registered public accounting firm on April 7, 2025, with immediate effect, for the fiscal year ending December 31, 2025.”
Marcum LLP resigned as auditor of Rani Therapeutics Holdings, Inc..
“On April 7, 2025, Marcum resigned as the independent registered public accounting firm of Rani Therapeutics Holdings, Inc.”
Rani Therapeutics Holdings, Inc. reported the three months ended March 31, 2024 results: net income Net loss for the three months ended March 31, 2024 was $14.8 million.
“Rani Therapeutics Holdings, Inc. (the “Company”) issued a press release providing a corporate update and announcing its financial results for the three months ended March 31, 2024.”
Rani Therapeutics Holdings, Inc. reported financial results for fourth quarter and year ended December 31, 2023.
“On March 20, 2024, Rani Therapeutics Holdings, Inc. (the “Company”) issued a press release providing a corporate update and announcing its financial results for the fourth quarter and year ended December 31, 2023.”
Rani Therapeutics Holdings, Inc. reported financial results for the third quarter ended September 30, 2023.
“On November 8, 2023, Rani Therapeutics Holdings, Inc. (the “Company”) issued a press release providing a corporate update and announcing its financial results for the third quarter ended September 30, 2023.”
Rani Therapeutics Holdings, Inc. reported the third quarter ended September 30, 2023 results: net income between $17.0 million and $19.0 million.
“Rani’s preliminary consolidated financial results for the third quarter ended September 30, 2023”
Rani Therapeutics Holdings, Inc. announced a restructuring with charges of approximately $0.3 million (reduction of the Company’s workforce by approximately 25%).
“On November 1, 2023, the Company committed to the Restructuring, which is a plan for strategic prioritization of its programs, expansion of its manufacturing and streamlining of its business operations to support potential near-term value drivers and long-term growth. The Restructuring provides for a reduction of the Company’s workforce by approximately 25%. As a result of the Restructuring, the Company estimates that it will incur approximately $0.3 million in costs of which nearly all are cash expenditures related to severance.”
Rani Therapeutics Holdings, Inc. entered into Standard Industrial/Commercial Multi-Tenant Lease - Net with BKM South Bay 240, LLC valued at $95,019.00 per month (effective 2023-11-01).
“On November 1, 2023, Rani Therapeutics, LLC (“Rani LLC”), a subsidiary of Rani Therapeutics Holdings, Inc. (the “Company”), and BKM South Bay 240, LLC (“Landlord”) entered into the Standard Industrial/Commercial Multi-Tenant Lease - Net (the “Lease”).”
Rani Therapeutics Holdings, Inc. reported second quarter ended June 30, 2023 results: net income Net loss for the three months ended June 30, 2023, was $18.7 million.
“On August 11, 2023, Rani Therapeutics Holdings, Inc. (the “Company”) issued a press release providing a corporate update and announcing its financial results for the second quarter ended June 30, 2023.”
Rani Therapeutics Holdings, Inc. entered into License and Supply Agreement with Celltrion, Inc. valued at Exclusive worldwide royalty-free license to intellectual property for adalimumab biosimilar product; (effective 2023-06-01).
“On June 1, 2023, Rani Therapeutics, LLC, an operating subsidiary of Rani Therapeutics Holdings, Inc. (“Rani”), and Celltrion, Inc. (“Celltrion”) entered into a License and Supply Agreement (the “License Agreement”). Under the License Agreement, Celltrion grants Rani an exclusive, worldwide, royalty-free license to certain intellectual property to make, use, sell, offer for sale, import and otherwise exploit an orally-administered therapeutic product using Rani’s oral delivery technology and Celltrion’s adalimumab biosimilar (“Product”) and to use certain information to support the manufacture, development and commercialization of Product.”
Rani Therapeutics Holdings, Inc. shareholders approved Ratification of the selection of Ernst & Young, LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2023 at the 2023-05-25 meeting.
“The Company’s stockholders ratified the selection of Ernst & Young, LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2023, as follows: For: 230,587,049 Against: 51 Abstain: 2,301”
Rani Therapeutics Holdings, Inc. shareholders approved Election of director nominees to hold office until the 2024 annual meeting of stockholders at the 2023-05-25 meeting.
“The Company’s stockholders elected the director nominees below, to hold office until the 2024 annual meeting of stockholders or until their successors are duly elected and qualified, as follows: For Withheld Broker Non-Votes Talat Imran 226,312,911 27,468 4,249,022 Mir Imran 226,125,068 215,311 4,249,022 Dennis Ausiello 226,152,615 187,764 4,249,022 Jean-Luc Butel 226,144,055 196,324 4,249,022 Laureen DeBuono 226,292,924 47,455 4,249,022 Andrew Farquharson 226,277,448 62,931 4,249,022 Malik Nanavaty 226,292,189 48,190 4,249,022 Lisa Rometty 226,314,568 25,811 4,249,022”
Rani Therapeutics Holdings, Inc. reported the three months ended March 31, 2023 results: net income $16.8 million.
“Net loss for the three months ended March 31, 2023 was $16.8 million, compared to $13.8 million for the same period in 2022, including non-cash charges primarily attributable to stock-based compensation expense of $4.0 million for the three months ended March 31, 2023, compared to $3.0 million for the same period in 2022.”
Lyn Baranowski departed as Director at Rani Therapeutics Holdings, Inc..
“On March 30, 2023, Ms. Lyn Baranowski notified Rani Therapeutics Holdings, Inc. (the “Company”) that she does not intend to stand for re-election at the 2023 annual meeting of stockholders of the Company (“Annual Meeting”).”
Rani Therapeutics Holdings, Inc. reported the fourth quarter and year ended December 31, 2022 results: net income Net loss for the three and twelve months ended December 31, 2022 was $17.3 million and $63.3 million, respectively.
“On March 22, 2023, Rani Therapeutics Holdings, Inc. (the “Company”) issued a press release providing a corporate update and announcing its financial results for the fourth quarter and year ended December 31, 2022.”
Rani Therapeutics Holdings, Inc. entered into License Agreement with Celltrion, Inc. (effective 2023-01-06).
“On January 6, 2023, Rani Therapeutics, LLC, an operating subsidiary of Rani Therapeutics Holdings, Inc. (“Rani”), and Celltrion, Inc. (“Celltrion”) entered into a License and Supply Agreement (the “License Agreement”).”
Rani Therapeutics Holdings, Inc. incurred term loan of $15 million with Avenue Venture Opportunities Fund, L.P..
“On December 29, 2022 (the “Borrowing Date”), Rani Therapeutics Holdings, Inc. (“Rani Holdings”) completed a draw down of $15 million under a Loan and Security Agreement and related Supplement dated August 8, 2022 (the “Loan Agreement”), by and among Rani Holdings, Rani Therapeutics, LLC and Rani Management Services, Inc., and Avenue Venture Opportunities Fund, L.P., a Delaware limited partnership.”
Lisa Rometty was elected as Director at Rani Therapeutics Holdings, Inc..
“On January 2, 2022, upon the recommendation of its Nominating and Corporate Governance Committee, the board of directors (the “Board”) of Rani Therapeutics Holdings, Inc. (the “Company”) elected Lisa Rometty as a director of the Company, effective January 3, 2022, with a term expiring at the Company’s next annual meeting of stockholders.”
Lyn Baranowski was elected as Director at Rani Therapeutics Holdings, Inc..
“On November 10, 2021, upon the recommendation of its Nominating and Corporate Governance Committee, the board of directors (the “Board”) of Rani Therapeutics Holdings, Inc. (the “Company”) elected Lyn Baranowski as a Director, effective immediately, with a term expiring at the Company’s next annual meeting of stockholders.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.